$SRPT News 7 gut checks before the stock market'
Post# of 144498
Posted On: 11/18/2013 7:05:16 PM
$SRPT News
7 gut checks before the stock market's opening bell 7:54 a.m. July 25, 2013 - Shawn Langlois
7 gut checks before the stock market's opening bell 8:00 a.m. July 24, 2013 - Shawn Langlois
Sarepta up 21% on plans to submit drug application 6:55 a.m. July 24, 2013 - Sara Sjolin
Ignore your feelings, obey the market 12:15 p.m. July 23, 2013 - The Trading Deck
For stock speculators, it’s down to two choices 11:10 a.m. June 27, 2013 - The Trading Deck
5 stocks insiders are betting on 11:15 a.m. June 25, 2013 - Insider Monkey
How to get the Nasdaq out of neutral 2:11 p.m. June 18, 2013 - The Trading Deck
Tuesday’s movers: Apple snaps 3-day losing streak 4:09 p.m. April 16, 2013 - Sue Chang
The market that can do no wrong? 10:14 a.m. March 26, 2013 - The Trading Deck
6 stocks positioning for breakouts 8:53 a.m. March 15, 2013 - The Trading Deck
3 speculative names for a market stuck in neutral 8:49 a.m. March 14, 2013 - The Trading Deck
Caesars, Zynga among charts to watch today 1:50 p.m. Feb. 28, 2013 - The Trading Deck
13 stocks for ’13 6:16 p.m. Jan. 3, 2013 - The Trading Deck
Dow, Nasdaq return to scene of the breakdown 12:02 p.m. Nov. 27, 2012 - Michael Ashbaugh
Dow, Nasdaq return to scene of the breakdown 11:46 a.m. Nov. 27, 2012 - Michael Ashbaugh
Charting the S&P 500’s precarious position 12:20 p.m. Nov. 13, 2012 - Michael Ashbaugh
Charting the S&P 500’s precarious position 11:46 a.m. Nov. 13, 2012 - Michael Ashbaugh
Charting the Election Day backdrop 12:09 p.m. Nov. 6, 2012 - Michael Ashbaugh
Charting the Election Day backdrop 11:34 a.m. Nov. 6, 2012 - Michael Ashbaugh
Nasdaq retesting the 200-day moving average 11:10 a.m. Oct. 25, 2012 - Michael Ashbaugh
Amarin, Sarepta And Vanda: Teachable Moments In Biotech 10:23 a.m. Nov. 17, 2013 - Seeking Alpha
Insider Trading Alert - TYL, OPK, SRPT, HAL And MLNX Traded By Insiders 11:45 a.m. Nov. 15, 2013 - TheStreet.com
Today's Perilous Reversal Stock: Sarepta Therapeutics (SRPT) 10:10 a.m. Nov. 15, 2013 - TheStreet.com
How to Trade Sarepta After the FDA Setback 6:00 a.m. Nov. 14, 2013 - TheStreet.com
Sarepta Therapeutics: No Longer A Momentum Play, But Long-Term Value Remains 3:30 a.m. Nov. 14, 2013 - Seeking Alpha
Analysts: BlackBerry Fundamentals Are Not Improving and 3 More Research Notes to Read 2:44 p.m. Nov. 13, 2013 - Wall St. Cheat Sheet
Sarepta Down on FDA's Response - Analyst Blog 12:10 p.m. Nov. 13, 2013 - Zacks.com
UPDATE: Deutsche Bank Downgrades Sarepta Therapeutics Following FDA Announcement That NDA Filing is Premature 9:17 a.m. Nov. 13, 2013 - benzinga.com
A Post-Mortem on Sarepta's Epic Explosion, Mea Culpa Included 6:47 a.m. Nov. 13, 2013 - TheStreet.com
VNDA Stock Nearly Doubles in One Day 3:49 a.m. Nov. 13, 2013 - InvestorPlace.com
Why Shares of SRPT Stock Sank 65% 3:09 a.m. Nov. 13, 2013 - InvestorPlace.com
Why Shares of SRPT Stock Sank 65% 3:09 a.m. Nov. 13, 2013 - InvestorPlace.com
Searching for Clarity 4:31 p.m. Nov. 12, 2013 - RealMoney.com
FDA Wants More Testing of Muscular-Dystrophy Drug 4:23 p.m. Nov. 12, 2013 - WSJ.com
Stocks Slip on Lackluster Earnings as Fed's Fisher Signals Pullback 4:21 p.m. Nov. 12, 2013 - TheStreet.com
Sarepta Therapeutics' CEO Discusses Q3 2013 Results - Earnings Call Transcript 2:45 p.m. Nov. 12, 2013 - Seeking Alpha
Analysts: Macy’s Estimates Are Overly Optimistic and 3 More Research Notes to Look Through 1:29 p.m. Nov. 12, 2013 - Wall St. Cheat Sheet
Signs of a Turning Point? 1:20 p.m. Nov. 12, 2013 - RealMoney.com
Sarepta Therapeutics Plunges On Negative FDA Report 1:20 p.m. Nov. 12, 2013 - Investors Business Daily
Sarepta Therapeutics: FDA Considers NDA Filing for Eteplirsen "Premature" 11:59 a.m. Nov. 12, 2013 - benzinga.com
Levi & Korsinsky, LLP Launches Investigation of SAREPTA THERAPEUTICS, INC. for Possible Violations of Federal Securities Laws 2:58 p.m. Nov. 13, 2013 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT 12:03 p.m. Nov. 13, 2013 - PR Newswire
Insider Trading Research for Micron, Hertz, Annaly Capital Management, Sarepta Therapeutics, Rackspace Hosting, and Tesla Motors 8:55 a.m. Nov. 13, 2013 - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sarepta Therapeutics, Inc. 3:00 p.m. Nov. 12, 2013 - PR Newswire
SRPT, HOLX, QUIK and VNDA added to NASDAQ Active Stock Watch List at GSR 10:21 a.m. Nov. 12, 2013 - ACCESSWIRE
Sarepta Therapeutics Announces Third Quarter 2013 Financial Results and Recent Corporate Developments 7:01 a.m. Nov. 12, 2013 - Marketwire
Critical Alerts For Micron Technology, Sarepta Therapeutics, Alliance Fiber Optic Products, Pfizer, and KB Home Released By InvestorsObserver 9:31 a.m. Nov. 11, 2013 - PR Newswire
Morning Research: Medivation Inc., ACADIA Pharma Inc., Sarepta Therapeutics Inc., and Cell Therapeutics Inc. 8:00 a.m. Nov. 11, 2013 - PR Newswire
Sarepta Therapeutics to Announce Third Quarter 2013 Financial Results and Corporate Update on November 12, 2013 8:30 a.m. Oct. 24, 2013 - Marketwire
Pre-Market Review: ACADIA Pharma Inc., Cell Therapeutics Inc., Sarepta Therapeutics Inc., and Medivation Inc. 9:05 a.m. Oct. 21, 2013 - PR Newswire
Parent Project Muscular Dystrophy and Sarepta Therapeutics Join Forces on Genetic Testing Program for Patients With Duchenne Muscular Dystrophy 8:31 a.m. Oct. 17, 2013 - Marketwire
Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy Community on October 17, 2013 4:30 p.m. Oct. 10, 2013 - Marketwire
Critical Alerts For Coca-Cola, Biogen Idec, Hewlett-Packard, Yum! Brands, and Sarepta Therapeutics Released By InvestorsObserver 9:31 a.m. Oct. 8, 2013 - PR Newswire
Cellular Biomedicine Has Multiple Near-Term Catalysts 10:27 a.m. Oct. 3, 2013 - ACCESSWIRE
Sarepta Therapeutics Introduces Online Resource Center on Exon Skipping for the Duchenne Muscular Dystrophy Community 8:31 a.m. Oct. 2, 2013 - Marketwire
Sarepta Therapeutics Announces Eteplirsen Demonstrates Continued Stability on Walking Test Through 96 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy 8:30 a.m. Sept. 26, 2013 - Marketwire
Technical Study: Cell Therapeutics Inc., ACADIA Pharmaceuticals Inc., Sarepta Therapeutics Inc., and Medivation Inc. 8:52 a.m. Sept. 25, 2013 - PR Newswire
SRPT, FB, CRUS and OMER added to NASDAQ Active Stock Watch List at GSR 9:02 a.m. Sept. 24, 2013 - ACCESSWIRE
Insider Trading Research for Sarepta Therapeutics, QUALCOMM, Sirius XM Radio, Yahoo, Annaly Capital Management, and Bank of America 8:55 a.m. Sept. 23, 2013 - PR Newswire
Five Star Equities Issues New Research Reports on CYCC, RNA, RVP and SRPT 8:40 a.m. Sept. 23, 2013 - ACCESSWIRE
7 gut checks before the stock market's opening bell 7:54 a.m. July 25, 2013 - Shawn Langlois
7 gut checks before the stock market's opening bell 8:00 a.m. July 24, 2013 - Shawn Langlois
Sarepta up 21% on plans to submit drug application 6:55 a.m. July 24, 2013 - Sara Sjolin
Ignore your feelings, obey the market 12:15 p.m. July 23, 2013 - The Trading Deck
For stock speculators, it’s down to two choices 11:10 a.m. June 27, 2013 - The Trading Deck
5 stocks insiders are betting on 11:15 a.m. June 25, 2013 - Insider Monkey
How to get the Nasdaq out of neutral 2:11 p.m. June 18, 2013 - The Trading Deck
Tuesday’s movers: Apple snaps 3-day losing streak 4:09 p.m. April 16, 2013 - Sue Chang
The market that can do no wrong? 10:14 a.m. March 26, 2013 - The Trading Deck
6 stocks positioning for breakouts 8:53 a.m. March 15, 2013 - The Trading Deck
3 speculative names for a market stuck in neutral 8:49 a.m. March 14, 2013 - The Trading Deck
Caesars, Zynga among charts to watch today 1:50 p.m. Feb. 28, 2013 - The Trading Deck
13 stocks for ’13 6:16 p.m. Jan. 3, 2013 - The Trading Deck
Dow, Nasdaq return to scene of the breakdown 12:02 p.m. Nov. 27, 2012 - Michael Ashbaugh
Dow, Nasdaq return to scene of the breakdown 11:46 a.m. Nov. 27, 2012 - Michael Ashbaugh
Charting the S&P 500’s precarious position 12:20 p.m. Nov. 13, 2012 - Michael Ashbaugh
Charting the S&P 500’s precarious position 11:46 a.m. Nov. 13, 2012 - Michael Ashbaugh
Charting the Election Day backdrop 12:09 p.m. Nov. 6, 2012 - Michael Ashbaugh
Charting the Election Day backdrop 11:34 a.m. Nov. 6, 2012 - Michael Ashbaugh
Nasdaq retesting the 200-day moving average 11:10 a.m. Oct. 25, 2012 - Michael Ashbaugh
Amarin, Sarepta And Vanda: Teachable Moments In Biotech 10:23 a.m. Nov. 17, 2013 - Seeking Alpha
Insider Trading Alert - TYL, OPK, SRPT, HAL And MLNX Traded By Insiders 11:45 a.m. Nov. 15, 2013 - TheStreet.com
Today's Perilous Reversal Stock: Sarepta Therapeutics (SRPT) 10:10 a.m. Nov. 15, 2013 - TheStreet.com
How to Trade Sarepta After the FDA Setback 6:00 a.m. Nov. 14, 2013 - TheStreet.com
Sarepta Therapeutics: No Longer A Momentum Play, But Long-Term Value Remains 3:30 a.m. Nov. 14, 2013 - Seeking Alpha
Analysts: BlackBerry Fundamentals Are Not Improving and 3 More Research Notes to Read 2:44 p.m. Nov. 13, 2013 - Wall St. Cheat Sheet
Sarepta Down on FDA's Response - Analyst Blog 12:10 p.m. Nov. 13, 2013 - Zacks.com
UPDATE: Deutsche Bank Downgrades Sarepta Therapeutics Following FDA Announcement That NDA Filing is Premature 9:17 a.m. Nov. 13, 2013 - benzinga.com
A Post-Mortem on Sarepta's Epic Explosion, Mea Culpa Included 6:47 a.m. Nov. 13, 2013 - TheStreet.com
VNDA Stock Nearly Doubles in One Day 3:49 a.m. Nov. 13, 2013 - InvestorPlace.com
Why Shares of SRPT Stock Sank 65% 3:09 a.m. Nov. 13, 2013 - InvestorPlace.com
Why Shares of SRPT Stock Sank 65% 3:09 a.m. Nov. 13, 2013 - InvestorPlace.com
Searching for Clarity 4:31 p.m. Nov. 12, 2013 - RealMoney.com
FDA Wants More Testing of Muscular-Dystrophy Drug 4:23 p.m. Nov. 12, 2013 - WSJ.com
Stocks Slip on Lackluster Earnings as Fed's Fisher Signals Pullback 4:21 p.m. Nov. 12, 2013 - TheStreet.com
Sarepta Therapeutics' CEO Discusses Q3 2013 Results - Earnings Call Transcript 2:45 p.m. Nov. 12, 2013 - Seeking Alpha
Analysts: Macy’s Estimates Are Overly Optimistic and 3 More Research Notes to Look Through 1:29 p.m. Nov. 12, 2013 - Wall St. Cheat Sheet
Signs of a Turning Point? 1:20 p.m. Nov. 12, 2013 - RealMoney.com
Sarepta Therapeutics Plunges On Negative FDA Report 1:20 p.m. Nov. 12, 2013 - Investors Business Daily
Sarepta Therapeutics: FDA Considers NDA Filing for Eteplirsen "Premature" 11:59 a.m. Nov. 12, 2013 - benzinga.com
Levi & Korsinsky, LLP Launches Investigation of SAREPTA THERAPEUTICS, INC. for Possible Violations of Federal Securities Laws 2:58 p.m. Nov. 13, 2013 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT 12:03 p.m. Nov. 13, 2013 - PR Newswire
Insider Trading Research for Micron, Hertz, Annaly Capital Management, Sarepta Therapeutics, Rackspace Hosting, and Tesla Motors 8:55 a.m. Nov. 13, 2013 - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sarepta Therapeutics, Inc. 3:00 p.m. Nov. 12, 2013 - PR Newswire
SRPT, HOLX, QUIK and VNDA added to NASDAQ Active Stock Watch List at GSR 10:21 a.m. Nov. 12, 2013 - ACCESSWIRE
Sarepta Therapeutics Announces Third Quarter 2013 Financial Results and Recent Corporate Developments 7:01 a.m. Nov. 12, 2013 - Marketwire
Critical Alerts For Micron Technology, Sarepta Therapeutics, Alliance Fiber Optic Products, Pfizer, and KB Home Released By InvestorsObserver 9:31 a.m. Nov. 11, 2013 - PR Newswire
Morning Research: Medivation Inc., ACADIA Pharma Inc., Sarepta Therapeutics Inc., and Cell Therapeutics Inc. 8:00 a.m. Nov. 11, 2013 - PR Newswire
Sarepta Therapeutics to Announce Third Quarter 2013 Financial Results and Corporate Update on November 12, 2013 8:30 a.m. Oct. 24, 2013 - Marketwire
Pre-Market Review: ACADIA Pharma Inc., Cell Therapeutics Inc., Sarepta Therapeutics Inc., and Medivation Inc. 9:05 a.m. Oct. 21, 2013 - PR Newswire
Parent Project Muscular Dystrophy and Sarepta Therapeutics Join Forces on Genetic Testing Program for Patients With Duchenne Muscular Dystrophy 8:31 a.m. Oct. 17, 2013 - Marketwire
Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy Community on October 17, 2013 4:30 p.m. Oct. 10, 2013 - Marketwire
Critical Alerts For Coca-Cola, Biogen Idec, Hewlett-Packard, Yum! Brands, and Sarepta Therapeutics Released By InvestorsObserver 9:31 a.m. Oct. 8, 2013 - PR Newswire
Cellular Biomedicine Has Multiple Near-Term Catalysts 10:27 a.m. Oct. 3, 2013 - ACCESSWIRE
Sarepta Therapeutics Introduces Online Resource Center on Exon Skipping for the Duchenne Muscular Dystrophy Community 8:31 a.m. Oct. 2, 2013 - Marketwire
Sarepta Therapeutics Announces Eteplirsen Demonstrates Continued Stability on Walking Test Through 96 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy 8:30 a.m. Sept. 26, 2013 - Marketwire
Technical Study: Cell Therapeutics Inc., ACADIA Pharmaceuticals Inc., Sarepta Therapeutics Inc., and Medivation Inc. 8:52 a.m. Sept. 25, 2013 - PR Newswire
SRPT, FB, CRUS and OMER added to NASDAQ Active Stock Watch List at GSR 9:02 a.m. Sept. 24, 2013 - ACCESSWIRE
Insider Trading Research for Sarepta Therapeutics, QUALCOMM, Sirius XM Radio, Yahoo, Annaly Capital Management, and Bank of America 8:55 a.m. Sept. 23, 2013 - PR Newswire
Five Star Equities Issues New Research Reports on CYCC, RNA, RVP and SRPT 8:40 a.m. Sept. 23, 2013 - ACCESSWIRE
(0)
(0)Scroll down for more posts ▼